Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · Real-Time Price · USD

0.3476

-0.0083 (-2.33%)

At close: Oct 2, 2026, 4:00 PM EDT

0.3690

+0.0214 (6.16%)

After-hours: Oct 2, 2026, 7:56 PM EDT

Heron Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	151.18	154.9	144.29	127.04	107.67	86.35
Revenue Growth	0.99%	7.36%	13.57%	17.99%	24.70%	-2.59%
Cost of Revenue	57.55	53.78	55.33	100.24	133.38	175.64
Gross Profit	93.63	101.13	88.95	26.81	-25.71	-89.3
Selling, General & Admin	104.5	103.67	100.48	119.82	143.55	127.13
Operating Expenses	104.5	103.67	100.48	119.82	143.55	127.13
Operating Income	-10.86	-2.54	-11.53	-93.02	-169.26	-216.43
Interest Expense	-14.21	-9.61	-6.03	-3.87	-2.47	-2.41
Interest & Investment Income	1.95	1.95	3.55	3.36	1.64	0.43
Other Non Operating Income (Expenses)	0.83	1.75	4.83	1.18	-6.32	-0.4
EBT Excluding Unusual Items	-22.3	-8.44	-9.18	-92.34	-176.42	-218.81
Merger & Restructuring Charges	-	-	-	-4.2	-5.4	-1.4
Gain (Loss) on Sale of Investments	-	-	0.01	-0	-	-
Asset Writedown	-0.41	-0.41	-4.41	-0.62	-0.21	-0.48
Other Unusual Items	-11.34	-11.34	-	-13.4	-	-
Pretax Income	-34.05	-20.2	-13.58	-110.56	-182.02	-220.68
Net Income	-34.05	-20.2	-13.58	-110.56	-182.02	-220.68
Net Income to Common	-34.05	-20.2	-13.58	-110.56	-182.02	-220.68
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	185	167	152	138	109	98
Shares Outstanding (Diluted)	185	167	152	138	109	98
Shares Change	20.47%	9.35%	10.36%	26.87%	10.57%	8.48%
EPS (Basic)	-0.18	-0.12	-0.09	-0.80	-1.67	-2.24
EPS (Diluted)	-0.18	-0.12	-0.09	-0.80	-1.67	-2.24
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-12.14	-27.91	-24.24	-60.33	-148.74	-206.38
Free Cash Flow Per Share	-0.07	-0.17	-0.16	-0.44	-1.37	-2.10
Gross Margin	61.93%	65.28%	61.65%	21.10%	-23.87%	-103.42%
Operating Margin	-7.19%	-1.64%	-7.99%	-73.22%	-157.20%	-250.65%
Profit Margin	-22.52%	-13.04%	-9.41%	-87.02%	-169.05%	-255.58%
Free Cash Flow Margin	-8.03%	-18.02%	-16.80%	-47.49%	-138.14%	-239.01%
EBITDA	-8.73	-0.22	-9.04	-90.12	-166.37	-213.41
EBITDA Margin	-5.78%	-0.14%	-6.26%	-70.93%	-154.52%	-247.15%
D&A For EBITDA	2.13	2.31	2.49	2.9	2.89	3.02
EBIT	-10.86	-2.54	-11.53	-93.02	-169.26	-216.43
EBIT Margin	-7.19%	-1.64%	-7.99%	-73.22%	-157.20%	-250.65%

SEC Filings: 10-K · 10-Q